NLS Pharmaceutics AG
23.1.2023 14:33:52 CET | ACCESS Newswire | Press release
- The orexin deficit is believed to be the root cause of narcolepsy
- Mazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep disorders
- Mazindol ER is a first in class, unique dual mechanism of action as pan-monoamine reuptake inhibitor and strong Orexin-2 partial receptor agonist
- Phase 2 clinical trials evaluating Quilience (mazindol ER) in the treatment of narcolepsy recently concluded, meeting the primary endpoint with high statistical significance
ZURICH, SWITZERLAND / ACCESSWIRE / January 23, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor (OX2R). Two identical studies measuring differing concentrations of mazindol ER confirmed significant OX2R partial agonist activity at 30μM or higher. Notably, findings show that mazindol ER showed strong OX2R partial agonist activity by cellular and nuclear receptor functional assays. Results showed pEC50 (a logarithm measure of drug potency expressing a concentration that is effective in producing 50% of the maximal response) values of 4.7 to 5 for mazindol on the OX2R, indicating a strong OX2R partial agonist.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. Orexin plays a critical role in regulating the sleep-wake cycle and the most common form of narcolepsy, type 1 (NT1), in which the individual experiences brief losses of muscle tone, known as or cataplexy, is caused by a lack of orexin in the brain due to destruction of the cells that produce it. Mazindol ER is an OX2R partial agonist that was developed to address the loss of orexin signaling in NT1. Currently available treatments for NT1 only address the associated symptoms but not the underlying loss of orexin.
"This result is very encouraging for understanding the mechanism of action of mazindol ER in the treatment of narcolepsy," said Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics. "This is a significant add-on therapeutic option in narcolepsy type 1 that includes excessive daytime sleepiness and the sudden loss of muscle tone, or cataplexy, when a person is awake. We now know that orexin is considered to play a crucial role in the sleep-wake cycle and narcolepsy is caused by severe loss of the orexin neurotransmitter in the lateral hypothalamus."
Additional pre-clinical in vivo studies are currently underway to confirm OX2R activity. A pilot study in OXR2 KO mice animal model compared favorably with investigational drug, TAK-925, an orexin 2 receptor agonist. Supplementary studies to further characterize OX2R activity as well as activity at OX1R are planned for the first half of 2023. NLS Pharmaceutics plans to present the study results at a scientific meeting later this year.
"The unique dual mechanism of action of mazindol ER seems to represent an advantage over previously studied compounds, as mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist. We are very optimistic about these studies combined with the promising results of our phase 2 program," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
The Phase 3 program for Quilience (mazindol ER) is currently on track to commence in mid- 2023.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
About Quilience®
The Company's lead product candidate, Quilience®, is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as Idiopathic Hypersomnia (IH), for which NLS recently obtained Orphan Disease Designation (ODD) from the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2 multi-center U.S. clinical study evaluating Quilience® in adult patients suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol® (Mazindol Controlled-Release) in adult patients suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses that mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist, the ability of mazindol ER to treat narcolepsy and the timing of the Phase 3 program for Quilience. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/736231/NLS-Pharmaceutics-Announces-New-In-Vitro-Data-Reconfirming-QuiliencesR-Mazindol-ER-Unique-Dual-Mechanism-of-Action-Involving-Significant-Orexin-2-Receptor-Activity
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
87% of HR Leaders Have Conducted or Plan Layoffs in 2026. New LHH Research Reveals How Integrated Outplacement and Targeted Redeployment Protect Future Talent and Support Those Who Must Leave21.4.2026 14:07:00 CEST | Press release
Only 19% of employees recognize redeployment programs that 77% of HR leaders say exist, revealing a critical visibility gap that prevents organizations from retaining future-critical talent and fulfilling their duty of care to departing employees. NEW YORK CITY, NY / ACCESS Newswire / April 21, 2026 / New research from LHH, a global talent solutions provider and business unit of the Adecco Group, finds that 87% of HR leaders say their organization has already conducted or is planning layoffs in the next 12 months, driven by skills displacement, AI transformation, and shifting market demands. At the same time, 62% of employers track rehiring costs and nearly three quarters of those organizations acknowledge that rehiring costs are more than targeted redeployment and mobility. The findings, published in LHH's The Mobility Breakdown: Redeployment and Outplacement Trends Report reveal that as workforce restructuring becomes continuous, most organizations lack integrated outplacement and ta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
